- Home
- BYRN vs CAPR Comparison
BYRN vs CAPR Comparison
Compare BYRN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- CAPR
- Stock Information
- Founded
- BYRN 2005
- CAPR 2005
- Country
- BYRN United States
- CAPR United States
- Employees
- BYRN N/A
- CAPR N/A
- Industry
- BYRN Industrial Machinery/Components
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYRN Miscellaneous
- CAPR Health Care
- Exchange
- BYRN Nasdaq
- CAPR Nasdaq
- Market Cap
- BYRN 607.8M
- CAPR 578.4M
- IPO Year
- BYRN N/A
- CAPR N/A
- Fundamental
- Price
- BYRN $26.27
- CAPR $15.22
- Analyst Decision
- BYRN Strong Buy
- CAPR Strong Buy
- Analyst Count
- BYRN 3
- CAPR 7
- Target Price
- BYRN $17.75
- CAPR $39.29
- AVG Volume (30 Days)
- BYRN 403.8K
- CAPR 684.9K
- Earning Date
- BYRN 04-04-2025
- CAPR 02-27-2025
- Dividend Yield
- BYRN N/A
- CAPR N/A
- EPS Growth
- BYRN N/A
- CAPR N/A
- EPS
- BYRN 0.10
- CAPR N/A
- Revenue
- BYRN $73,417,000.00
- CAPR $23,228,045.00
- Revenue This Year
- BYRN $104.84
- CAPR N/A
- Revenue Next Year
- BYRN $29.23
- CAPR $74.85
- P/E Ratio
- BYRN $257.99
- CAPR N/A
- Revenue Growth
- BYRN 70.65
- CAPR 65.33
- 52 Week Low
- BYRN $7.79
- CAPR $3.52
- 52 Week High
- BYRN $32.58
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- BYRN 43.11
- CAPR 56.15
- Support Level
- BYRN $27.60
- CAPR $13.62
- Resistance Level
- BYRN $32.58
- CAPR $15.62
- Average True Range (ATR)
- BYRN 1.98
- CAPR 0.84
- MACD
- BYRN -0.55
- CAPR 0.21
- Stochastic Oscillator
- BYRN 8.14
- CAPR 81.63
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia and Canada.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.